159 related articles for article (PubMed ID: 10091802)
1. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
[TBL] [Abstract][Full Text] [Related]
2. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
4. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
5. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.
Yung WK; Kyritsis AP; Gleason MJ; Levin VA
Clin Cancer Res; 1996 Dec; 2(12):1931-5. PubMed ID: 9816151
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb R; Mutch DG
Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
[TBL] [Abstract][Full Text] [Related]
7. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
9. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
Gross MW; Altscher R; Brandtner M; Haeusser-Mischlich H; Chiricuta IC; Siegmann AD; Engenhart-Cabillic R
Clin Neurol Neurosurg; 2005 Apr; 107(3):207-13. PubMed ID: 15823676
[TBL] [Abstract][Full Text] [Related]
10. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
[TBL] [Abstract][Full Text] [Related]
12. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
Traina TA; Sabbatini P; Aghajanian C; Dupont J
Gynecol Oncol; 2004 Oct; 95(1):235-41. PubMed ID: 15385138
[TBL] [Abstract][Full Text] [Related]
13. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group.
Kirby S; Gertler SZ; Mason W; Watling C; Forsyth P; Aniagolu J; Stagg R; Wright M; Powers J; Eisenhauer EA
Neuro Oncol; 2005 Apr; 7(2):183-8. PubMed ID: 15831236
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; McMeekin DS
Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
[TBL] [Abstract][Full Text] [Related]
19. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.
Bernier-Chastagner V; Grill J; Doz F; Bracard S; Gentet JC; Marie-Cardine A; Luporsi E; Margueritte G; Lejars O; Laithier V; Mechinaud F; Millot F; Kalifa C; Chastagner P
Cancer; 2005 Dec; 104(12):2792-7. PubMed ID: 16265674
[TBL] [Abstract][Full Text] [Related]
20. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
